Results 281 to 290 of about 157,341 (380)

Catecholamines Differ in Their Capacity to Form Melanin. [PDF]

MicroPubl Biol
Rayes L, Njus D.
europepmc   +1 more source

Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes, Daniel G. Di Luca, Connie Marras, Erik Boot, Ryan K.C. Yuen, Anthony E. Lang, Anne S. Bassett   +6 more
wiley   +1 more source

Spectro-electrochemistry of guaiacol oxidation: tracking intermediates in a membrane-separated cell with <i>in situ</i> attenuated total reflectance-infrared spectroscopy.

Faraday Discuss
Schwartmann SMK, Biggiero M, Deelen S, Baumgartner B, Weckhuysen BM.   +4 more
europepmc   +1 more source

The dynamic chemistry of the boron-nitrogen bond. [PDF]

Chem Sci
Frateloreto F, Capocasa G, De Angelis M, Sandri G, Lanzalunga O, Massera C, Di Stefano S.   +6 more
europepmc   +1 more source

Catechol 1,2-dioxygenase from Rhodococcus rhodochrous NCIMB 13259

, 1997
Philip Strachan
openalex   +2 more sources

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source

Leveraging catechol chemistry to tackle toughness-softness-work capacity tradeoff in reprogrammable liquid crystal actuators. [PDF]

Nat Commun
He E, Wu Y, Liang H, Xu H, Ji J, Yang Z, Wang Y, Wei Y, Ji Y.   +8 more
europepmc   +1 more source

Catechol Amines in Bananas

Journal of Pharmacy and Pharmacology, 1958
openaire   +2 more sources

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig, Lennert Sitzmann, Doreen Hartenstein, Marion Labisch, Chi Wang Ip, Jens Volkmann, Christine Daniels   +6 more
wiley   +1 more source

Stable coexistence and phenol-degradation expression of Cupriavidus sp. strain P-10 and Comamonas thiooxydans strain R2 in phenol-competitive chemostat culture. [PDF]

Appl Microbiol Biotechnol
Suzuki K, Aziz FAA, Honjo M, Din ARJBM, Amano K, Tashiro Y, Futamata H.   +6 more
europepmc   +1 more source